MERCK & CO. INC.
MRKNYSETrading Snapshot
- Day Range
- $144.50 β $148.80
- 52-Week Range
- $78.03 β $156.92
- Volume
- $9.96B
- Avg Volume
- $10.68B
- Shares Outstanding
- 2.47B
- Next Earnings
- Nov 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $64.93B
- Last Q Revenue
- $16.61B
- P/E Ratio
- 118.0
- P/S Ratio
- 5.5x
- EPS (TTM)
- $1.28
- Dividend Yield
- 2.29%
- Dilution (1yr)
- β2.1%
Why Investors Own MRK
- βHigh-growth profile β revenue up +50.7% YoY with expanding US Equity exposure.
- βHealthy economics β 27% gross margin and 9% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
MERCK & CO. INC.
MRKAbout MERCK & CO. INC.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
FDA Expands Merck's Welireg Label for a New Kidney Cancer Indication
FDA expands MRK's Welireg label for advanced kidney cancer, adding a third indication as sales climb and the drug gains wider use.

US drugmakers turn to China for licensing deals
Merck on Monday agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global βrights to an experimental cancer drug, making βit the latest US drugmaker to license China-developed medicines.

Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
Merck said on Monday it would pay up to $2.13 billion under a βglobal licensing deal with China's SciBrunch Therapeutics βfor rights to develop, manufacture and sell an experimental cancer treatment.

Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (βSciBrunchβ), today announced that they have entered into an exclusive global